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Abstract
Background: Persistent airway infection is a hallmark feature of cystic fibrosis (CF). However, increasingly it has
been observed that non-classical pathogens may transiently infect CF lower airways. Streptococcus pyogenes (Group
A Streptococcus; (GAS)) is an uncommon but potentially dangerous cause of community-acquired pneumonia. Our
aim was to determine the incidence, natural history, and clinical impact of GAS infections in CF and phenotypically
and genotypically characterize the isolates.
Methods: We retrospectively evaluated the Calgary Adult CF Clinic biobank to identify adults with at least one GAS
isolate. Patient demographics, medical and pulmonary exacerbation (PEx) histories were evaluated. The primary
outcome was PEx occurrence at incident GAS culture. Secondary outcomes evaluated were changes in lung
function and PEx frequency following GAS isolation. Isolates were assessed for extra-cellular virulence factor
production capacity and ability to produce quorum sensing (AI-2). Isolates were genotyped using pulse-field gel
electrophoresis (PFGE).
Results: Fifteen individuals who cultured GAS twenty times were identified. At the time of GAS isolation, 47 %
(7/15) of subjects experienced a PEx and half of these (4/7) were severe. Individuals were more likely to have a
PEx at the time of the index GAS isolate compared to the preceding visit (RR = 6.0, 95 % CI 0.82–43.0, p = 0.08),
particularly if GAS was the numerically dominant sputum pathogen (RR = 6.5, 95 % CI 1.00–43.0, p = 0.009). There
were no changes in PEx frequency or rate of lung function decline following GAS. None of the patients developed
chronic airways infection, bacteremia, necrotizing pneumonia or empyema. Susceptibility was universal to common
anti-Streptococcal antibiotics and anti-Pseudomonal antibiotics commonly used in CF, with the exception of
azithromycin. GAS isolates varied in their production of protease, DNase, and AI-2 but these did not correlate with
PEx, and none produced elastase, chrondrotin sulfatase or H202. One patient had prolonged carriage with the same
isolate and two patients had isolates with similar PFGE patterns.
Conclusions: GAS was an uncommon lower respiratory pathogen of adults with CF. Identification of GAS in
sputum was frequently associated with PEx, particularly when numerically dominant. However, transient GAS
infection did not result in chronic infection nor appreciably change long-term disease trajectory.
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Background
Cystic fibrosis (CF) is the most common lethal auto-
somal recessive disease amongst Caucasians [1]. Typic-
ally affected organs include the sinuses, lungs,
gastrointestinal system and the male reproductive sys-
tem. Pulmonary complications (both acute and chronic)
are the primary cause of morbidity and mortality in the
adult CF population [2, 3]. CF lungs are classically char-
acterized by viscous secretions as well as impaired
mucociliary clearance [4, 5]. These factors compromise
airway clearance creating an optimal environment for
bacterial colonization, inflammation, chronic infection,
and eventually, bronchiectasis.
The cultured microbiome of the CF respiratory system
is well-characterized and unique from other forms of
chronic lung disease. Nevertheless, our understanding of
lung microbiology in the CF population continues to
evolve. Traditional perceptions focused on chronic
colonization with classical CF pathogens such as Pseudo-
monas aeruginosa, Staphylococcus aureus, Haemophilus
influenzae, and Burkholderia cepacia complex [6]. Other
microorganisms such as Stenotrophomonas maltophilia,
Achromobacter species, and mycobacteria have been
identified as emerging CF pathogens in the last two de-
cades [6, 7]. Whereas traditional pathogens like P. aeru-
ginosa and B. cenocepacia have clearly been associated
with adverse outcomes, the clinical implications are less
clear with many emerging pathogens [8–10]. Further-
more, it is apparent that CF airways disease may exist in
both stable (classical CF pathogens) and dynamic states
(non-classical pathogens whose presence in the CF air-
ways disease is usually only temporary). How these tran-
sient infections affect CF outcomes is entirely unknown.
Consequently, clinicians are posed with unique manage-
ment challenges when these atypical microbes are iso-
lated from the lower respiratory tracts of CF patients.
One such organism is Group A Streptococcus (Strepto-
coccus pyogenes), a common human pathogen that is rarely
observed from CF lungs. S. pyogenes are β-hemolytic Gram
positive cocci and facultative anaerobes. Its ability to cause
hemolysis on blood agar plates allows it to be distinguished
from other more indolent streptococci [11].
Furthermore, GAS has numerous virulence factors
that enable it to evade host immune defenses, colonize
epithelial surfaces, and cause infection [12, 13].
GAS can cause a variety of different infections with a
spectrum of disease severity ranging from mild to inva-
sive and life threatening [14]. While it most often mani-
fests as pharyngeal, soft tissue or skin infections, it can
rarely manifest as a respiratory infection. Although GAS
only accounts for a small proportion of community ac-
quired pneumonia in the general population, it tends to
cause more severe and aggressive pulmonary infections
and often manifest as empyema [14]. The prevalence,
natural history and clinical effect of GAS in the CF
population are unknown. Herein we set out to determine
the natural history of GAS and outcomes associated with
GAS infection in adults with CF. Furthermore, we
sought to characterize GAS to determine if genotypic or
phenotypic features were associated with disease.
Methods
Population
We retrospectively evaluated the Calgary Adult CF
Clinic Biobank (CACFB; a prospectively collected and
inventoried repository of every bacterial isolate from
every CF sputum sample collected from each clinical en-
counter since 1978). Patients provide prospective con-
sent for collection and research at enrollment into the
clinic. Ethics for the collection and analysis was granted
by the Conjoint Health Research Ethics Board (E-23087).
Patients who cultured GAS at least once were included.
There were no exclusion criteria other than age under
18 years.
Clinical data collection
The study design was retrospective and encompassed
the two years preceding and two years following each
GAS isolation. We collected baseline patient demo-
graphic information, dynamic spirometry data, exacerba-
tion data, medications at the time of GAS isolate, and
the presence of CF and non CF-related co-morbidities.
Quantitative microbiology (reported as colony forming
unit (CFU)/ml of sputum) was performed on each sam-
ple as is standard of care within our institution.
The primary outcome was the occurrence of pulmon-
ary exacerbation (PEx) at the time of index GAS isolate
compared to the preceding clinical visit. A PEx was de-
fined based on a retrospective chart evaluation to iden-
tify documentation which met Fuchs’ criteria and for
which acute antibacterial therapy was prescribed [15]. A
severe PEx was one requiring intravenous antibiotics
and/or hospitalization. Secondary outcomes included:
(1) change in predicted forced expiratory volume in one
second (FEV1) at the time of GAS identification versus
the last clinic visit; (2) PEx frequency in individuals be-
fore and after the first GAS isolate; (3) rate of FEV1 de-
cline before and after GAS, (4) severe complications of
GAS infection; and (5) rate of progression to chronic
infection.
Characterization of GAS
Genotyping and phenotyping were carried out on viable
GAS isolates. GAS were genotyped using pulsed field gel
electrophoresis (PFGE) to assess for clonality using the
protocol of Sibley et al. [16]. Restriction digestion was
performed independently with both SmaI and ApaI.
PFGE profiles were compared using BioNumerics
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Version 7.0 (Applied Maths, Austin TX). Strains that
had banding patterns ≥80 % identical were a priori con-
sidered related, conforming to the Tenover criteria,
where isolates with 1 to 3 band differences were still
considered related [17]. Dendrograms were generated at
2.0 % position tolerance using the unweighted pair-
group method with arithmetic mean (UPGMA) and the
Sørensen-Dice similarity coefficient.
Antibiotic susceptibility testing was performed as per
Thornton et al. [18]. Briefly, colonies from a 24-hour
incubation on Columbia Blood Agar (CBA) were sus-
pended in 0.85 % saline solution to a 0.5 McFarland
standard and spread on the Mueller-Hinton Blood Agar
(MHBA) plates with a sterile cotton swab. Antibiotic
discs were obtained from Oxoid (Nepean, Ontario) and
stored at 4 °C until use. Antibiotics used in this investi-
gation are those commonly used in CF and those fre-
quently prescribed for GAS infection. The following
antimicrobial discs were stamped on with a disc dispen-
ser or manually placed: penicillin G (P, 10 U), ceftriax-
one (CRO, 30 μg), ceftazidime (CAZ, 30 μg),
azithromycin (AZM, 15 μg), erythromycin (E, 15 μg),
clindamycin (CDA, 2 μg), and levofloxacin (LEV, 15 μg).
The “D-test” for inducible clindamycin resistance was
performed. Plates were incubated for 20 to 24 h at 37 °C
with 5 % carbon dioxide (CO2) after which zone diame-
ters were measured and compared to established break-
points to determine susceptible (S), intermediate (I) and
resistant (R) status as per CLSI guidelines [19, 20].
There were six exo-enzyme assays of GAS virulence
factors capable of breaking down host products to aid
in bacterial survival performed using cultures grown
at 37 °C with 5 % CO2; each exo-enzyme assay in-
volved the creation of a media with specific materials
to test for the virulence factor as per the methods of
Grinwis et al. [21]. Production of virulence factors
was scored as positive (production of the factor) or
negative (no evidence of this particular factor).
Autoinducer-2 (A1- 2) is a universal quorum sensing
molecule enabling interspecies signaling and communi-
cation. Cell free supernatants of each isolates were
screened using a Vibrio harveyi bioassay for detection of
the AI-2 using the methods of Grinwis et al. [21, 22]. In
brief, overnight cultures of GAS were incubated in
Todd-Hewitt-Yeast broth with 0.5 % yeast extract
(Bacto) for 24 h at 37 °C with 5 % CO2. 1 ml was trans-
ferred to a 1.5 ml tube and centrifuged at 2300 g for
5 min and filtered through 0.2 um membrane. 400 ul
was stored at −20 °C until use. The supernatant was
mixed with the Vibrio harveyi MM32 reporter strain
(luxS-, luxN-, deficient in production of AI-2 but
sensitive to its production) and grown for 24 h in Todd-
Hewitt- Yeast broth at 30 °C. At 24 h luciferase produc-
tion (counts per second) was measured using a Wallac
Victor2 microplate reader (Perkin Elmer, Waltham, MA)
and reported as positive if >2.5 fold-above the negative
control. All assays were performed in triplicate and for
statistical analysis, Tukey’s multiple comparison test was
performed using Prism 5.0.
Statistical analysis
Demographic data was analyzed using descriptive statis-
tics. Chi-Squared testing was used to determine the rela-
tive risk (RR) of PEx at the time of GAS isolation
compared to the preceding visit as well as to determine
if various clinical or microbiological factors affected the
odds of PEx at GAS isolation. Wilcoxon rank- sum tests
were used to compare the PEx rates and rate of FEV1
change in the 2 years before and 2 years following the
index GAS isolates. Nonparametric tests were applied
given the small sample size. Analysis was performed
with STATA/IC 13.1 software (Stata- Corp, TX, USA).
Results
Population characteristics
Between 1978 and 2013, there were fifteen individuals
from a cohort of 318 adults with CF (4.7 %) who had
GAS isolated from their sputum. Thirteen patients cul-
tured GAS only once, and two patients had repeated cul-
tures for a total of 20 GAS isolates present within the
CACFB. One patient (Patient 6) had three consecutive
sputum samples growing GAS over 161 days, but subse-
quently cleared. Another patient (Patient 15) had inter-
mittent GAS in their sputum on four separate occasions
spanning 8.6 years. No patient became a chronic GAS
carrier.
There were a comparable number of men and women
(8 and 7, respectively) with a median age of 26 at the
time of first GAS isolate (IQR 19 to 33 years) (Table 1).
The majority had baseline airflow obstruction (86 %),
with a median FEV1 percent predicted of 50 % (IQR 35
to 82.6) (Tables 1 & 2). Most individuals were lifelong-
long nonsmokers and had multi-organ CF disease in
addition to bronchiectasis (Table 1). At the time of
incident culture, half the group (7/15) was on chronic
suppressive antibiotics (inhaled tobramycin or oral azi-
thromycin) and a similar number received long-acting
inhalers (inhaled corticosteroid, long acting beta agonist,
or a combination ICS/LABA) (Table 1). Only one third
were using an inhaled mucolytic and/or hypertonic sa-
line (Table 1). Information regarding frequency, quality
and nature of chest physiotherapy could not be reliably
ascertained.
Primary outcome - risk of pulmonary exacerbation
At the time of first GAS isolation, 47 % (7/15) of individ-
uals experienced a PEx and approximately half of these
(4/7) were severe. Of all encounters in which GAS was
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identified, 45 % (9/20) were associated with a PEx; 44 %
(4/9) of which were severe (Table 3). Relative to the pre-
ceding clinical visit, patients had a trend towards in-
creased PEx risk at incident GAS isolation (RR = 6.0,
95 % CI 0.82–43.0, p = 0.08). If GAS was the numerically
dominant organism in the collected sputum, risk was
further increased (RR = 6.5, 95 % CI 1.00–43.0, p =
0.009); however, there was no specific log threshold for
GAS above which PEx was more likely. Risk of PEx was
not affected by the individual’s age, sex, severe airflow
obstruction at the preceding visit (as defined by % pre-
dicted FEV1 < 40), or presence of specific chronic cul-
tured microorganisms (as defined by Leeds Criteria)
[23]. Furthermore, the risk of PEx was not influenced by
the use of chronic antibiotics, inhalers, mucolytics or
hypertonic saline (data not shown).
Exacerbation frequency and lung function
Of the 76 PEx during the study period, 38 occurred be-
fore and 29 after the first GAS isolate, respectively. The
median number of PEx per patient was 2.5 (IQR 0 to 5)
in the two years preceding index GAS isolate, compared
to 2 (IQR 0 to 3) in the two following years. GAS did
not increase the frequency of PEx in the two years after
the index GAS isolate compared to the two preceding
years (RR = 1.07, 95 % CI 0.71 to 1.63, p = 0.77); the fre-
quency of severe PEx was also unchanged (RR = 1.04,
95 % CI 0.5 to 2.13, p = 1.00). In fact, 60 % (9/15) of in-
dividuals had a lower PEx frequency after the first GAS
isolate.
Only 15 % (2/13) of subjects had a significant decrease
in their FEV1 (≥10 %) at incident GAS isolate compared
to the last visit and a minority of samples collected at
any time with GAS (2/17) were associated with a de-
creased FEV1. Furthermore, the rate of FEV1 decline did
not significantly differ in the two years following the
index isolate compared to the two preceding years; this
was true for both the decline in absolute FEV1, (p = 0.27)
and % predicted FEV1 (p = 0.72).
Clinical outcomes
Bacteremia, necrotizing pneumonia, and empyema were
not observed with any of the GAS isolates. In the two
years post index isolate, no individuals required initi-
ation of chronic oxygen therapy or listing for lung
transplant.
Table 1 Baseline demographics of adult cystic fibrosis patients with known S. pyogenes Sputum isolates








TISd AZMe LABAf ICSg CFhCo-
morbidities
1 19 M F508del F508del I N 2.62 (74) 4.09(100) Y N N N DIOS, B
2 19 M F508del 3849+1G->A I N 3.07 (71) - N N N N Liver, S
3 34 M F508del E56K S N 3.87 (106) 4.98(115) N N N N None
4 18 F M1101K M1101K I N 2.22 (71) 3.06(93) Y N N N
5 24 F F508del F508del I Unknown 1.19 (35) 1.84(47) N N N N DIOS
6 28 F F508del F508del I N 2.39 (89) 3.72(122) N N N N IGT,DIOS
7 38 F F508del R347H S Unknown 2.15 (77) 3.14(95) N N N N S
8 48 M F508del F508del I N 2.30 (54) 4.79(90) Y Y Y N IGT
9 19 M 1717-1G->A Unknown S N 3.73 (82) 4.55(85) N N N N S
10 21 M F508del F508del I Y 2.63 (40) 3.61(84) N N N N DIOS
11 33 F F508del R334W I N 1.11 (71) 2.34(74) N N N N DIOS
12 26 M G542x Unknown I Y 2.96 (69) 4.99(100) N Y Y N CFRD
13 26 F Unknown Unknown I N 2.80 (88) 4.10(108) Y N N N CFRD,B, S,
DIOS,
14 24 M F508del F508del I N 3.84 (84) 5.80(115) Y N N Y Liver
15 28 F M1101K M1101K I N 2.67 (91) 3.37 (101) N N N N B,S
I insufficient, S sufficient, Y yes, N no
a Age at time of first S. pyogenes isolation.
bBaseline FEV1 forced expiratory volume in one second recorded 2 years prior to the index GAS isolate
c Baseline FVC forced volume capacity recorded 2 years prior to the index GAS isolate
d TIS Chronic inhaled tobramycin therapy
e AZM Chronic azithromycin
f LABA Long-acting beta agonist
g ICS Inhaled corticosteroid
h CF Comorbidities, DIOS Distal Ileal Obstruction Syndrome, B osteoporosis, Liver liver disease, S sinus disease, IGT Impaired Glucose Tolerance, CFRD CF related
diabetes
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Phenotypic and genotypic characterization of GAS
Antibiotic susceptibility testing data was available on all
isolates to penicillin. Of the 20 isolates available in the
biobank, 11 were viable for further phenotypic assess-
ment and were compared against GAS ATCC 19615. All
viable GAS strains were sensitive to levofloxacin, penicil-
lin G, and ceftriaxone (Table 3). Azithromycin resistance
was rare (8 %), and not observed in patients on chronic
macrolide therapy. CLSI breakpoints for GAS do not
exist, however ceftazidime (an agent commonly used in
CF) demonstrated considerably inferior anti-GAS activ-
ity (median KB zone of 33 mm). No clindamycin resist-
ance, or inducible resistance with the D-test was
observed. The majority (10/11) of GAS isolates produced
DNAse and only one-quarter (3/11) produced elastase
(Table 3). None of the GAS isolates produced protease,
chondroitin sulfatase, or hydrogen peroxide (Table 3).
AI-2 production was observed from all but one GAS isola
te. There was no association between the production of
particular virulence factors and the occurrence of PEx at
isolation (data not shown).
Genotypic assessment of strain relatedness to assess
for natural history of infection and potential for patient-
patient spread was evaluated. PFGE profiles of the 11
viable isolates from the biobank and a control strain
ATCC 19615 were performed. Patient A004 isolated the
same strain of GAS over three months demonstrating
persistent carriage of a single isolate was possible. Two
patients A004 and A143 had isolates with the same
PFGE profile with both SmaI (Fig. 1) and ApaI (not
shown), although these isolates were collected three
years apart suggesting patient-patient transmission was
not a factor.
Discussion
Our study is the first to investigate the prevalence of
GAS and its clinical effects in the adult CF population.
S. pyogenes is a common organism that can affect
healthy individuals of any age [14]. While GAS may
transiently colonize the upper respiratory tract as a com-
mensal organism (as is the case in 15 to 20 % of healthy
children), it has also proven itself as a major human
Table 2 S.pyogenes sputum isolates and exacerbation status in adult cystic fibrosis patients
Isolate Patienta Date of Isolation CFUb GAS Most Abundant Reduced FEV1
c PExd Chronic Bacterial Infections
1 1 08-1997 106 N N N PA
2 2 04-2010 104 N Y Ya None
3 3 08-2013 104 Y N/I Y None
4 4 09-2010 106 Y N N PA, MSSA
5 5 09-2010 107 Y N/I Y MSSA, HI
6 6 12-2001 107 Y N N MSSA
7 6 02-2002 107 Y N N None
8 6 05-2002 107 Y N Ya None
9 7 07-2006 107 Y Y Y MSSA, HI
10 8 07-2012 105 N N N PA
11 9 10-1995 108 Y N Ya MSSA, HI
12 10 05-1999 107 N N N MSSA, Bc
13 11 01-2001 107 Y N N MSSA
14 12 10-2012 105 Y N N PA
15 13 11-2012 106 Y N Y PA
16 14 11-2006 107 Y N N PA, MSSA
17 15 10-2000 106 N N N PA, MSSA
18 15 11-2002 105 N N Y None
19 15 02-2009 106 N N Y None
20 15 05-2009 103 N N N None
a Refer to Table 1
b CFU colony forming units/ml of sputum
c Reduced FEV1 reduction in reduction in FEV1 by >10% at time of visit compared to baseline FEV1
d PEx pulmonary exacerbation as defined by Fuch’s Criteria and the need for antibiotics
* Severe PEx pulmonary exacerbation requiring hospitalization and/or parenteral antibiotics
e PA Pseudomonas aeruginosa, MSSA Methicillin sensitive S. aureus, HI Haemophilus influenzae, Bc Burkholderia cenocepacia
Y yes, N no, N/I no information, N/I no information
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Fig. 1 SmaI restriction digest pulse field gel electrophoresis of S. pyogenes recovered from CF sputum. A = patient number, date indicated
as year/month/day
Table 3 Antibiotic susceptibility and virulence factors of S. pyogenes sputum isolates from adult cystic fibrosis patients
Patient Iso-late Antibiotic susceptibility Virulence Factor Productionb
PEN LVX CAZa (mm) CRO CLI AZM Protease Elastase H2O2 DNAse Chondroitin Sulfatase AI-2
1 1 S S 38 S S S P N N P N N
2 2 S - - - S - - - - - - -
3 3 S - - - - - - - - - - -
4 4 S S 37 S S S N N N P N P
5 5 S S 33 S S S P N N P N P
6 6 S - - - - - - - - - - -
6 7 S - - - - - - - - - - -
6 8 S - - - - - - - - - - -
7 9 S S 25 S S S N N N P N P
8 10 S S 30 S S R N N N P N P
9 11 S S 34 S S S N N N P N P
10 12 S S 34 S S S N N N P N P
11 13 S S 40 S S S N N N P N P
12 14 S - - - S - - - - - - -
13 15 S S 33 S S S N N N N N P
14 16 S - - - - - - - - - - -
15 17 S - - - - - - - - - - -
15 18 S - - - - - - - - - - -
15 19 S S 35 S S S N N N P N P
15 20 S S 38 S S S N N N P N P







(-) Indicates frozen isolate could not be successfully recovered.
S Sensitive, I Intermediate, R=Resistant
a = CLSI breakpoints do not exist for ceftazidime. Results reported as Kirby-Bauer zone sizes.
b Production of virulence factors reported as strains producing those factors; P positive (Strains produced this virulence factor), or N=negative
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pathogen [24]. It is responsible for a broad spectrum of
disease including pharyngitis, scarlet fever, rheumatic
fever, cellulitis, necrotizing fasciitis, toxic shock syn-
drome, and pneumonia [14]. GAS infections can range
from mild to life threatening; severe disease is not lim-
ited to those with chronic illness or immune comprom-
ise [14]. Globally, GAS is responsible for a significant
burden of disease; every year it accounts for 110 million
skin and soft tissue infections [11], 660 000 cases of
invasive infection [11] and over 294 000 deaths [25].
From a pulmonary standpoint, GAS is an infrequent
but important cause of pneumonia [26]. While it only
accounts for a small percentage of community acquired
pneumonia (CAP) in adults, S. pyogenes tends to cause
more severe and invasive infection compared to com-
mon CAP pathogens [14]. Furthermore, GAS has a
higher likelihood of resulting in necrotizing pneumonia,
progression to empyema and/or hemorrhagic pleural
effusion [13, 27]. Mortality rates for GAS pneumonia
range between 20 and 38 %, which is similar to that of
necrotizing fasciitis [13, 14].
Although S. pyogenes is a major global pathogen, little
is known about its role in CF lung disease. Given the po-
tential for GAS to cause exceptional virulence and the
compromised innate immunity of CF lungs, we hypothe-
sized that GAS may lead to adverse clinical outcomes in
this population. There is a paucity of GAS epidemiologic
data in the CF literature, with prior studies reporting
prevalence of 0.8 % (2/258) [28] and 0.9 % (4/495) [29],
respectively. Over 34 years, we identified that five per-
cent of patients isolated GAS on at least one occasion.
However, the presence of GAS increased the risk of PEx
relative to the preceding clinic visit, particularly if
present as the numerically dominant sputum pathogen.
This finding may warrant treating individuals with GAS
in their sputum with anti-GAS treatments in order to
potentially avoid an ensuing PEx. However, other factors
including exacerbation of chronically infecting patho-
gens, and inter-current upper respiratory viral illnesses
could also have contributed (although these factors were
just as likely in comparator clinical visits).
Within CF, it is clear that mere culture status may not
convey the entire story. Indeed, differential pathogenic
potential has been observed with the expression of a
number of phenotypic traits of classical CF pathogens
including P. aeruginosa, Bcc, and S. aureus. For example,
compared to patients with chronic methicillin-sensitive
S. aureus (MSSA) infection, those with chronic
methicillin-resistant S. aureus (MRSA) have an increased
risk of death [30]. Patients with MRSA have increased
rates of lung function decline [31] and are less likely to
recover lung function following PEx [32]. In patients
with chronic P. aeruginosa infections, its conversion to a
hyper-alginate producing, mucoid phenotype is associated
with progressive decline in lung function, increased risk of
hospitalization and reduced survival [8, 33–36]. The op-
posite appears true in Bcc chronically infected patients,
where mucoidy appears protective and patients with non-
mucoid isolates experience an exaggerated rate of clinical
decline [37, 38]. Even the ability to persist within the CF
lung seems to be influenced by specific phenotypic traits
of P. aeruginosa causing initial infections [39]. The pheno-
types that are associated with these strains may themselves
not be directly involved in disproportionate lung disease,
but rather they may be an indirect marker. Accordingly,
we sought to characterize easily assayable and important
virulence traits within infecting GAS strains to determine
if these factors disproportionally modified PEx risk.
The GAS isolated from CF airways were typical of
GAS reported in other diseases [40]. We identified vari-
able expression of virulence factors, which has previ-
ously been reported [41]. Of the limited virulence
factors assessed, expression did not increase risk for oc-
currence of PEx at the time of isolation. Almost all GAS
isolates produced AI-2, a diffusible cell-cell signaling
molecule enabling inter-species bacterial communication
on cell density [42, 43]. Either directly (GAS mediated
primary effects) or indirectly (through induction of
quorum sensing in patients chronically colonized with
pathogens such as P. aeruginosa), GAS may be able to
trigger a PEx [44].
The antibiotic sensitivity profile of our strains was
similar to that of other S. pyogenes epidemiologic studies
[40, 45], with the exception of a complete absence of
clindamycin resistance in our few isolates. Interestingly,
our study along with several small studies [40, 45], have
not found high rates of macrolide or fluoroquinolone re-
sistance, as reported in larger studies (despite their fre-
quent use in CF). Indeed, this may suggest that those
GAS in CF are not unrecognized chronic endogenous
lower respiratory tract flora in these individuals but ra-
ther newly acquired transient organisms not previously
exposed to antibiotics. Importantly, our GAS strains
were sensitive to antibiotics commonly used in the em-
piric treatment of CF PEx, although ceftazidime, an anti-
biotic commonly used in the empiric PEx management,
should not be used where GAS is involved. Nearly all
strains were sensitive to azithromycin; this raises the
possibility that chronic azithromycin may suppress GAS
and prevent initial colonization. Indeed, registry data
suggests that 60–70 % of CF patients with chronic P.
aeruginosa infection and 22 % of CF patients without
chronic P. aeruginosa receive chronic macrolide therapy
and this may account for its low observed incidence in
our cohort [46, 47].
PFGE has been shown to be similarly effective at differ-
entiating commonly infecting clones of GAS as other
established typing modalities including emm gene typing
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[48–50]. Using PFGE we demonstrated strain persistence
in those patients with repeated positive cultures, rather
than repeated new infections with different strains. We
did identify two patients with the same GAS isolate by
PFGE, but propose this was unlikely to be patient-patient
spread. Whereas typical CF pathogens are rare and oppor-
tunistic of the general population, GAS commonly colo-
nizes the upper respiratory tract in the general population
and common strains persist in locals for extended period
of times [51, 52]. Furthermore, GAS from these patients
were identified > 2.5 years apart with multiple negative
cultures in the ensuing time period making CF patient-
patient transmission biologically implausible.
Members of the genus Streptococcus have not tradition-
ally been considered CF respiratory pathogens. However,
using a combination of semi-selective agars and high
density sampling, high rates of Viridans Group Strepto-
cocci (VGS) have universally been identified [53–55]. The
Streptococcus anginosus group, in particular, is increas-
ingly thought to have a role in CF and its emergence as
numerically dominant organism has been observed in a
large subset of PEx [54]. Traditional clinical microbiology
protocols have been developed to overlook VGS. However,
GAS is easily identifiable as beta-hemolysis is a defining
feature (present in 99 % of isolates) [56], and as such is
more likely to be distinguished from oropharyngeal
streptococci using traditional culture techniques.
The role of bacteria in CF airways disease has been
viewed through the lens of contributing to chronic pro-
gressive lung disease [57, 58]. Indeed, when assessing
traditional CF pathogens such as P. aeruginosa and B.
cepacia complex, as well as emerging organisms such as
S. maltophilia, this model holds true. However, increas-
ingly organisms not typically associated with CF airways
disease including the Enterobactericeae, Pneumococ-
cus, and GAS are seen to transiently colonize the air-
ways [8, 59, 60]. The impact of these organisms on
short-term and long-term outcomes are for the most
part unknown. Given that transient colonization/infection
with respiratory viruses has been shown to produce short
term deleterious effects either through direct pathogenesis
or indirectly through resident microflora, so too might
transient bacterial pathogens [61]. Indeed, while an acute
impact on patient well-being was observed with incident
GAS infection, long term effects were not noted, nor
should they be expected. This highlights the concept that
emerging CF pathogens may not necessarily manifest as
chronic infections, as is often seen with P. aeruginosa, S.
aureus, and Bcc.
The main limitations of the study are the retrospective
design and wide confidence intervals relating to small
sample size and few events. Despite trying to account for
factors that could influence the risk of PEx, we were un-
able to control for differences in chest physiotherapy
quality and frequency as well as adherence to medications.
We also lacked documentation regarding potential con-
founding viral and/or environmental triggers for PEx. Fu-
ture studies assessing potential short-term impact of
transient airway colonizers are warranted based on the
data herein.
Conclusion
GAS was an uncommon, transient lower respiratory
pathogen in our population of adults with CF. In our co-
hort, identification of GAS in sputum, particularly as the
dominant organism, was associated with an increased PEx
risk. However, GAS colonization of the lower airways was
transient and, as such, did not impact lung function and
did not appreciably change the disease trajectory.
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